沙库巴曲缬沙坦钠在社区应用的综述
摘要
本文综述了沙库巴曲缬沙坦钠在社区中的应用。详细阐述了其作用机制、在心力衰竭治疗中的重要地位、在社区常见心血管疾病管理中的应用、安全性以及在特殊人群中的使用注意事项。同时结合相关研究文献，对该药物在社区医疗实践中的优势与挑战进行了分析，旨在为社区医疗工作者合理使用该药物提供参考。
关键词
参考
McMurray JJ, Packer M, Desai AS, et al. Angiotensin - neprilysin inhibition versus enalapril in heart failure[J]. New England Journal of Medicine, 2014, 371(11):993 - 1004.
McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. New England Journal of Medicine, 2019, 381(21):1995 - 2008.
Smith TG, Gong J, Handberg EM, et al. Effects of sacubitril - valsartan on clinical outcomes in patients with heart failure with reduced ejection fraction in a community setting[J]. Circulation: Heart Failure, 2017, 10(12):e004479.
Solomon SD, Claggett B, Lewis EF, et al. Effect of sacubitril - valsartan on physical function and quality of life in patients with heart failure and preserved ejection fraction: results from the PARAGON - HF trial[J]. Circulation, 2019, 140(17):1333 - 1344.
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. European Heart Journal, 2018, 39(33):3021 - 3104.
Velazquez EJ, Morrow DA, DeVore AD, et al. Zestril in acute myocardial infarction study (ZEST) investigators. Valsartan in acute myocardial infarction[J]. New England Journal of Medicine, 2003, 349(20):1893 - 1906.
Senni M, Redfield MM. Heart failure in the elderly[J]. Circulation, 2011, 123(8):945 - 956.
Refbacks
- 当前没有refback。